ArticleJournal of pain research2010
Pregabalin for the management of fibromyalgia syndrome.
Article in Journal of pain research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2023Pooled it
- Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study.BMC musculoskeletal disorders · 2011Trial
- Rise of Pregabalin Poisoning and Abuse Cases in Serbia: A Ten-Year Retrospective Study.International journal of general medicine · 2023Article
- Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis.Scientific reports · 2022Article
- The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.Current neurology and neuroscience reports · 2021Review
- Attenuation of reserpine-induced fibromyalgia via ROS and serotonergic pathway modulation by fisetin, a plant flavonoid polyphenol.Experimental and therapeutic medicine · 2020Article
- Pregabalin as a Pain Therapeutic: Beyond Calcium Channels.Frontiers in cellular neuroscience · 2020Review
- Treatment Patterns Associated with ACR-Recommended Medications in the Management of Fibromyalgia in the United States.Journal of managed care & specialty pharmacy · 2016Article
- Pregabalin abuse among opiate addicted patients.European journal of clinical pharmacology · 2013Article
- Monotherapy or combination therapy for fibromyalgia treatment?Current rheumatology reports · 2012Review
- The FIBRO System: A Rapid Strategy for Assessment and Management of Fibromyalgia Syndrome.Therapeutic advances in musculoskeletal disease · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This last article in a three-part series on approved medications for managing fibromyalgia syndrome (FMS) reviews pregabalin (Lyrica(®)). Pregabalin was the first drug approved for FMS management and, as an anticonvulsant, differs from the other approved agents that are antidepressants. Pregabalin inhibits presynaptic excitatory neurotransmitter release by blocking α(2)δ calcium channels. Five randomized, placebo-controlled trials have demonstrated pregabalin reduces pain and improves sleep and health-related quality of life in FMS patients. While indicated dosing is 300-450 mg divided twice daily, initial dosing of 25-50 mg at night is recommended owing to side effects including somnolence, dizziness, and cognitive dysfunction. Since side effects such as weight gain and peripheral edema are dose-related, uptitration in weekly increments based on tolerability and therapeutic response is recommended. Due to its lack of protein binding and negligible hepatic metabolism, pregabalin can be safely combined with other medications and used in patients with renal failure when the dose is appropriate. Pregabalin may worsen sedation when combined with central nervous system depressants. Pregabalin should be discontinued gradually. Pregabalin-treated patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior. Pregabalin in combination with the other approved medications may be synergistic in treating FMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.